Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Marco Sorio et al.|Journal of Clinical Oncology|2010Cited by 167
The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapyAlessandro Rambaldi, Corrado Tarella, Cristina Boschini et al.|American Journal of Hematology|2013Cited by 65
Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term SurvivalCorrado Tarella, Alessandro Rambaldi, Angela Gueli et al.|PLoS ONE|2014Cited by 26
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphomaSimone Ferrero, Marco Ladetto, Luigia Monitillo et al.|Annals of Hematology|2013Cited by 20
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trialRiccardo Bruna, Corrado Tarella, Fabio Benedetti et al.|Haematologica|2019Cited by 19